TransMedics Group (NASDAQ:TMDX) Trading Down 4.4% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) shares fell 4.4% during trading on Wednesday . The stock traded as low as $62.80 and last traded at $62.80. 598,790 shares were traded during mid-day trading, a decline of 43% from the average session volume of 1,047,481 shares. The stock had previously closed at $65.71.

Analysts Set New Price Targets

Several research firms recently commented on TMDX. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler cut their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Performance

The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 64.77 and a beta of 2.06. The stock’s 50 day moving average is $92.92 and its 200 day moving average is $130.29. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the previous year, the company earned ($0.12) EPS. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. Analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $8,180,642.53. This represents a 12.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 19,417 shares of company stock worth $2,240,738 in the last quarter. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC raised its stake in shares of TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Principal Financial Group Inc. grew its holdings in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after purchasing an additional 146,115 shares during the period. Hood River Capital Management LLC bought a new position in shares of TransMedics Group in the second quarter valued at $18,854,000. Canada Pension Plan Investment Board bought a new position in shares of TransMedics Group in the second quarter valued at $16,086,000. Finally, F M Investments LLC bought a new position in shares of TransMedics Group in the second quarter valued at $10,957,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.